实用肿瘤杂志2017，Vol.32Issue(4)：291-296,6.
EGFR突变晚期NSCLC患者MDT诊治报道
MDT management of an advanced NSCLC patient with EGFR mutation
郁佳 1周彩存 1吴凤英 1张世佳 2陈淑琴 3刘鸿程 4武春燕 5史景云 6梁世雄 7任胜祥1
作者信息
- 1. 同济大学附属上海市肺科医院肿瘤科,上海 200433
- 2. 河南大学附属淮河医院呼吸科,河南 开封 475000
- 3. 张家港市中医院呼吸内科,江苏 张家港 215600
- 4. 同济大学附属上海市肺科医院胸外科,上海 200433
- 5. 同济大学附属上海市肺科医院病理科,上海 200433
- 6. 同济大学附属上海市肺科医院影像科,上海 200433
- 7. 同济大学附属上海市肺科医院放疗科,上海 200433
- 折叠
摘要
Abstract
We report a patient with advanced non-small-cell lung cancer (NSCLC)and epidermal growth factor re-ceptor (EGFR)mutation,who showed different responses to EGFR-tyrosine kinase inhibitors (TKIs)and subsequently benefited from multidisciplinary team (MDT)management.The patient was diagnosed with stage Ⅳ adenocarcinoma of the left lung by CT guided lung puncture,with metastasis in the lung hilus,mediastina,bilateral lung and brain.Genetic screen-ing detected a deletion in exon 19 of EGFR.The patient received EGFR-TKIs as the first line therapy.After treatment,the left lung lesion showed persistent response,but the lesion in the right lung was progressively enlarged.A second biopsy from the right lung lesion revealed squamous cell carcinoma.The patient then received chemotherapy and regional radiation for the lesion in the right lung.All of the lesions were well controlled afterwards.With several MDT discussions,an individual-ized therapy was implemented and the survival was prolonged.关键词
癌,非小细胞肺/病理学/癌,非小细胞肺/诊断/基因,erbB-1/突变/综合疗法Key words
carcinoma,non-small-cell lung/pathology/carcinoma,non-small-cell lung/diagnosis/genes,erbB-1/mu-tation/combined modality therapy分类
医药卫生引用本文复制引用
郁佳,周彩存,吴凤英,张世佳,陈淑琴,刘鸿程,武春燕,史景云,梁世雄,任胜祥..EGFR突变晚期NSCLC患者MDT诊治报道[J].实用肿瘤杂志,2017,32(4):291-296,6.
